Why Noxadem Works
Dr. Jack Fisher, a Board Certified Plastic Surgeon, Associate Clinical Professor of Plastic Surgery at Vanderbilt University Medical Center, and former researcher at the Mayo Clinic is the Noxadem Medical Director and explains how he came upon the Noxadem solution: “I was investigating various remedies for Demodex mites that live in the scalp and hair follicles. One of my patients reported to me that the use of the Noxadem formula cleared his rosacea inflammation. Further investigation into the effects of Demodex mites on rosacea led to the development of the Noxadem regimen.”
After Dr. Fisher noted this relationship Noxadem began working with national skin care authority Dr. Peter Pagliese. The research and development of the patented technology in Noxadem Serum is overseen by a Scientific Advisory Panel and includes seven doctors from institutions such as Vanderbilt University Medical Center, Iowa State University, The University of British Columbia, University of Rochester, and University of California at Riverside. Through their efforts Noxadem developed the outstanding products available today, making it possible to relieve the redness, irritation and sensitivity of rosacea.
These microscopic, parasitic demodex mites favor the facial areas and play a part in provoking rosacea symptoms such as redness, inflammation and flushing. First, Noxadem gets rid of the mites. Noxadem Serum uses a patented system of natural plant oils such as rosemary, wintergreen, cinnamon and thyme in a special formulation that effectively eliminates these mites. Their soothing anti-oxidant, anti-inflammatory, anti-bacterial, and anti-fungal properties calms skin inflammation and the soreness caused by rosacea. The result is dramatically clearer skin that is soothed and calmed by the Noxadem Serum.
Noxadem has a proven track record with satisfied clients from every part of the United States. The technology used in Noxadem Serum is not available in any other products on the market. It is protected by 20 patents, with 30 more pending, along with several million dollars in research.
